Keith A Hermanstyne1, Glenn-Milo Santos2, Eric Vittinghoff3, Deirdre Santos4, Grant Colfax5, Phillip Coffin6. 1. University of California, Los Angeles Robert Wood Johnson Foundation Clinical Scholars Program, 10920 Wilshire Boulevard, Suite 710, Los Angeles, CA 90024, USA. Electronic address: khermanstyne@mednet.ucla.edu. 2. San Francisco Department of Public Health, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102, USA. Electronic address: glenn-milo.santos@sfgov.org. 3. University of California-San Francisco, 185 Berry Street, Lobby 5, Suite 5700, San Francisco, CA 94107-1762, USA. Electronic address: eric@biostat.ucsf.edu. 4. San Francisco Department of Public Health, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102, USA. Electronic address: Deirdre.Santos@sfdph.org. 5. San Francisco Department of Public Health, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102, USA. Electronic address: grant_colfax@yahoo.com. 6. San Francisco Department of Public Health, 25 Van Ness Avenue, Suite 500, San Francisco, CA 94102, USA. Electronic address: phillip.coffin@sfdph.org.
Abstract
BACKGROUND:Methamphetamine use has been previously associated with poor medication adherence, but, to date, there have been no studies that have conducted event-level analyses on correlates of medication adherence in studies of pharmacologic agents for methamphetamine dependence. METHODS: We pooled data from two previous, randomized controlled trials (using bupropion and mirtazapine, respectively) for methamphetamine dependence and used a mixed effects logistic model to examine correlates of daily opening of the medication event monitoring system (MEMS) cap as a repeated measure. We explored whether periods of observed methamphetamine use via urine testing were associated with study medication adherence based on MEMS cap openings. RESULTS: We found a significant negative association between methamphetamine-urine positivity and event-level study medication adherence as measured by MEMS cap openings (AOR: 0.69; 95% CI: 0.49-0.98). In addition, age (AOR: 1.07; 95% CI: 1.02-1.11) and depressive symptoms (AOR: 0.78; 95% CI: 0.64-0.90) were significantly associated with adherence. Finally, participants were more likely to open their study medication bottles on days when they presented for in-person urine testing. CONCLUSIONS: Our event-level analysis shows that methamphetamine use can be associated with reduced medication adherence as measured by MEMS cap openings in pharmacologic trials, which corroborates prior research. These findings may suggest that medication adherence support in pharmacologic trials among methamphetamine users may be needed to improve study compliance and could be targeted towards periods of time when there are more likely to not open their study medication pill bottles.
RCT Entities:
BACKGROUND:Methamphetamine use has been previously associated with poor medication adherence, but, to date, there have been no studies that have conducted event-level analyses on correlates of medication adherence in studies of pharmacologic agents for methamphetamine dependence. METHODS: We pooled data from two previous, randomized controlled trials (using bupropion and mirtazapine, respectively) for methamphetamine dependence and used a mixed effects logistic model to examine correlates of daily opening of the medication event monitoring system (MEMS) cap as a repeated measure. We explored whether periods of observed methamphetamine use via urine testing were associated with study medication adherence based on MEMS cap openings. RESULTS: We found a significant negative association between methamphetamine-urine positivity and event-level study medication adherence as measured by MEMS cap openings (AOR: 0.69; 95% CI: 0.49-0.98). In addition, age (AOR: 1.07; 95% CI: 1.02-1.11) and depressive symptoms (AOR: 0.78; 95% CI: 0.64-0.90) were significantly associated with adherence. Finally, participants were more likely to open their study medication bottles on days when they presented for in-person urine testing. CONCLUSIONS: Our event-level analysis shows that methamphetamine use can be associated with reduced medication adherence as measured by MEMS cap openings in pharmacologic trials, which corroborates prior research. These findings may suggest that medication adherence support in pharmacologic trials among methamphetamine users may be needed to improve study compliance and could be targeted towards periods of time when there are more likely to not open their study medication pill bottles.
Authors: Terry R Barclay; Charles H Hinkin; Steven A Castellon; Karen I Mason; Matthew J Reinhard; Sarah D Marion; Andrew J Levine; Ramani S Durvasula Journal: Health Psychol Date: 2007-01 Impact factor: 4.267
Authors: Charles H Hinkin; Terry R Barclay; Steven A Castellon; Andrew J Levine; Ramani S Durvasula; Sarah D Marion; Hector F Myers; Douglas Longshore Journal: AIDS Behav Date: 2007-03
Authors: Moupali Das; Deirdre Santos; Tim Matheson; Glenn-Milo Santos; Priscilla Chu; Eric Vittinghoff; Steve Shoptaw; Grant N Colfax Journal: AIDS Date: 2010-04-24 Impact factor: 4.177
Authors: Marie Krousel-Wood; Tareq Islam; Paul Muntner; Elizabeth Holt; Cara Joyce; Donald E Morisky; Larry S Webber; Edward D Frohlich Journal: Ann Behav Med Date: 2010-12
Authors: Charles H Hinkin; David J Hardy; Karen I Mason; Steven A Castellon; Ramani S Durvasula; Mona N Lam; Marta Stefaniak Journal: AIDS Date: 2004-01-01 Impact factor: 4.177
Authors: Ahmed M Elkashef; Richard A Rawson; Ann L Anderson; Shou-Hua Li; Tyson Holmes; Edwina V Smith; Nora Chiang; Roberta Kahn; Frank Vocci; Walter Ling; Valerie J Pearce; Michael McCann; Jan Campbell; Charles Gorodetzky; William Haning; Barry Carlton; Joseph Mawhinney; Dennis Weis Journal: Neuropsychopharmacology Date: 2007-06-20 Impact factor: 7.853
Authors: Matthew J Mimiaga; David W Pantalone; Katie B Biello; Jackie M White Hughto; John Frank; Conall O'Cleirigh; Sari L Reisner; Arjee Restar; Kenneth H Mayer; Steven A Safren Journal: AIDS Care Date: 2019-03-19
Authors: Steffen J Schmidt; Viktoria S Wurmbach; Anette Lampert; Simone Bernard; Walter E Haefeli; Hanna M Seidling; Petra A Thürmann Journal: Eur J Clin Pharmacol Date: 2020-04-01 Impact factor: 2.953